Fig. 5
From: Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma
Immune modulation after GD2 specific 4SCAR-T cell infusion. A Hematoxylin and eosin (H&E) staining, IHC staining for GD2, CD3, CD4, CD8 an CD68 in pre- and post-GD2 specific 4SCAR-T cell infusion specimens from Patient 01. B Multiplex immunofluorescence staining of GD2, CD8 and CD163 in pre- and post-GD2 specific 4SCAR-T cell infusion specimens from Patient 01. C Circulating levels of IL-6, TNF-α, and IFNγ in cerebrospinal fluid (CSF) from Patient 01. (D) Circulating levels of IL-6 and TNF-α in serum from Patient 01